Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer

At the beginning of the COVID-19 pandemic, patients with primary and secondary immune disorders—including patients suffering from cancer—were generally regarded as a high-risk population in terms of COVID-19 disease severity and mortality. By now, scientific evidence indicates that there is substantial heterogeneity regarding the vulnerability towards COVID-19 in patients with immune disorders. In this review, we aimed to summarize the current knowledge about the effect of coexistent immune disorders on COVID-19 disease severity and vaccination response. In this context, we also regarded cancer as a secondary immune disorder. While patients with hematological malignancies displayed lower seroconversion rates after vaccination in some studies, a majority of cancer patients’ risk factors for severe COVID-19 disease were either inherent (such as metastatic or progressive disease) or comparable to the general population (age, male gender and comorbidities such as kidney or liver disease). A deeper understanding is needed to better define patient subgroups at a higher risk for severe COVID-19 disease courses. At the same time, immune disorders as functional disease models offer further insights into the role of specific immune cells and cytokines when orchestrating the immune response towards SARS-CoV-2 infection. Longitudinal serological studies are urgently needed to determine the extent and the duration of SARS-CoV-2 immunity in the general population, as well as immune-compromised and oncological patients.

[1]  J. Casanova,et al.  Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia. , 2023, Annual review of immunology.

[2]  Á. Kinyó,et al.  Complexity of the Immune Response Elicited by Different COVID-19 Vaccines, in the Light of Natural Autoantibodies and Immunomodulatory Therapies , 2023, International journal of molecular sciences.

[3]  A. Tan,et al.  COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients , 2023, Vaccine: X.

[4]  P. Tabares,et al.  STAT1 overexpression triggers aplastic anemia: a pilot study unravelling novel pathogenetic insights in bone marrow failure , 2023, Clinical and Experimental Medicine.

[5]  H. Wildiers,et al.  Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13) , 2023, Autoimmunity Reviews.

[6]  N. Brunetti,et al.  Electrocardiographic Pathological Findings Caused by the SARS-CoV-2 Virus Infection: Evidence from a Retrospective Multicenter International Cohort Longitudinal Pilot Study of 548 Subjects , 2023, Journal of cardiovascular development and disease.

[7]  Antonio Giovanni Solimando,et al.  Can vitamin D status influence seroconversion to SARS-COV2 vaccines? , 2022, Frontiers in Immunology.

[8]  M. Bonifazi,et al.  Early administration of tofacitinib in COVID‐19 pneumonitis: An open randomised controlled trial , 2022, European journal of clinical investigation.

[9]  D. Ribatti,et al.  SARS-CoV-2 and Endothelial Cells: Vascular Changes, Intussusceptive Microvascular Growth and Novel Therapeutic Windows , 2022, Biomedicines.

[10]  C. Foti,et al.  SARS-CoV-2 and Skin: New Insights and Perspectives , 2022, Biomolecules.

[11]  M. Martinez-Urbistondo,et al.  Systemic Autoimmune Diseases in Patients Hospitalized with COVID-19 in Spain: A Nation-Wide Registry Study , 2022, Viruses.

[12]  B. LaFleur,et al.  Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis , 2022, European Journal of Cancer.

[13]  Zhuo Li,et al.  Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis , 2022, European Journal of Cancer.

[14]  A. Sette,et al.  Humoral and cellular immune memory to four COVID-19 vaccines , 2022, Cell.

[15]  F. Nikbakht,et al.  COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety , 2022, Frontiers in Endocrinology.

[16]  G. Giardino,et al.  The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet) , 2022, Journal of Clinical Immunology.

[17]  M. Mulligan,et al.  Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease , 2022, The Lancet Rheumatology.

[18]  A. Allegra,et al.  Involvement of Il-33 in the Pathogenesis and Prognosis of Major Respiratory Viral Infections: Future Perspectives for Personalized Therapy , 2022, Biomedicines.

[19]  O. Resta,et al.  Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection , 2022, Pathogens and global health.

[20]  P. Moss The T cell immune response against SARS-CoV-2 , 2022, Nature Immunology.

[21]  M. Diamond,et al.  Innate immunity: the first line of defense against SARS-CoV-2 , 2022, Nature Immunology.

[22]  A. Bilici,et al.  Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study , 2022, Future oncology.

[23]  S. Tangye,et al.  Severe COVID‐19 represents an undiagnosed primary immunodeficiency in a high proportion of infected individuals , 2022, Clinical & translational immunology.

[24]  Bryan D. Bryson,et al.  JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia. , 2022, Med.

[25]  P. Leone,et al.  Impact of Antigen Presentation Mechanisms on Immune Response in Autoimmune Hepatitis , 2022, Frontiers in Immunology.

[26]  E. Callaway Beyond Omicron: what’s next for COVID’s viral evolution , 2021, Nature.

[27]  Weihao Shao,et al.  Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis , 2021, International Journal of Infectious Diseases.

[28]  J. Underwood,et al.  Treatment of chronic or relapsing COVID-19 in immunodeficiency , 2021, Journal of Allergy and Clinical Immunology.

[29]  H. Gendelman,et al.  Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions , 2021, Frontiers in Immunology.

[30]  David W. McDonald,et al.  Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[31]  M. Dimopoulos,et al.  Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine , 2021, British journal of haematology.

[32]  A. Sette,et al.  Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells , 2021, Science.

[33]  S. Steinberg,et al.  Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors , 2021, JTO Clinical and Research Reports.

[34]  F. Baldanti,et al.  Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study , 2021, Clinical Microbiology and Infection.

[35]  F. Baldanti,et al.  A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study , 2021, ESMO Open.

[36]  B. Baradaran,et al.  A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery , 2021, Genes.

[37]  A. Paradiso,et al.  Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection , 2021, Journal of clinical medicine.

[38]  E. Holmes,et al.  After the pandemic: perspectives on the future trajectory of COVID-19 , 2021, Nature.

[39]  F. Rovida,et al.  Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study , 2021, International Journal of Infectious Diseases.

[40]  R. Scheuermann,et al.  Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.

[41]  G. De Pergola,et al.  COVID-19 and the Endocrine System: A Comprehensive Review on the Theme , 2021, Journal of clinical medicine.

[42]  J. Izopet,et al.  Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients , 2021, The New England journal of medicine.

[43]  L. Cerbone,et al.  Serological response to COVID-19 vaccination in patients with cancer older than 80 years , 2021, Journal of Geriatric Oncology.

[44]  G. Curigliano,et al.  COVID-19 vaccines in patients with cancer , 2021, The Lancet Oncology.

[45]  Bjoern Peters,et al.  SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19 , 2021, Cell Host & Microbe.

[46]  A. Sisó-Almirall,et al.  SARS-CoV-2 infection in patients with systemic autoimmune diseases. , 2021, Clinical and experimental rheumatology.

[47]  G. Giardino,et al.  Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity , 2021, The Journal of Allergy and Clinical Immunology: In Practice.

[48]  R. Bruno,et al.  SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay , 2021, Clinical Microbiology and Infection.

[49]  F. Giardina,et al.  Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice , 2021, Nature.

[50]  Jia Xin Yee,et al.  Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset , 2021, Med.

[51]  J. Schultze,et al.  COVID-19 and the human innate immune system , 2021, Cell.

[52]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[53]  A. Iafrate,et al.  COVID-19-neutralizing antibodies predict disease severity and survival , 2020, Cell.

[54]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[55]  Adam C. Labonte,et al.  Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway , 2020, Scientific Reports.

[56]  V. Procacci,et al.  Short-Term Variations in Neutrophil-to-Lymphocyte and Urea-to-Creatinine Ratios Anticipate Intensive Care Unit Admission of COVID-19 Patients in the Emergency Department , 2021, Frontiers in Medicine.

[57]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[58]  Smita Y. Patel,et al.  COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience , 2020, Journal of Allergy and Clinical Immunology.

[59]  C. Peano,et al.  Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19 , 2020, Nature Immunology.

[60]  A. Iwasaki,et al.  Interferon deficiency can lead to severe COVID , 2020, Nature.

[61]  G. Curigliano,et al.  Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2 , 2020, Annals of Oncology.

[62]  B. Lambrecht,et al.  Coronavirus disease 2019 in patients with inborn errors of immunity: An international study , 2020, Journal of Allergy and Clinical Immunology.

[63]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[64]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[65]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[66]  J. Tregoning,et al.  Vaccines for COVID‐19 , 2020, Clinical and experimental immunology.

[67]  M. Netea,et al.  Trained Innate Immunity, Epigenetics, and Covid-19. , 2020, The New England journal of medicine.

[68]  P. Sopp,et al.  Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.

[69]  Arthur S Slutsky,et al.  Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.

[70]  Bernd Bodenmiller,et al.  A distinct innate immune signature marks progression from mild to severe COVID-19 , 2020, bioRxiv.

[71]  Aaron M. Rosenfeld,et al.  Comprehensive mapping of immune perturbations associated with severe COVID-19 , 2020, Science Immunology.

[72]  M. Gianfrancesco,et al.  Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. , 2020, Current opinion in rheumatology.

[73]  M. Peluso,et al.  Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV. , 2020, The Journal of infectious diseases.

[74]  Shaoying Huang,et al.  The cytokine storm and COVID‐19 , 2020, Journal of medical virology.

[75]  S. Fonseca,et al.  Immune and Metabolic Signatures of COVID-19 Revealed by Transcriptomics Data Reuse , 2020, Frontiers in Immunology.

[76]  Jian-Piao Cai,et al.  Attenuated Interferon and Proinflammatory Response in SARS-CoV-2–Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation , 2020, The Journal of infectious diseases.

[77]  V. Torri,et al.  COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.

[78]  J. Blay,et al.  High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR , 2020, European Journal of Cancer.

[79]  L. Staudt,et al.  Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 , 2020, Science Immunology.

[80]  Kemesha S Gabbidon,et al.  The Impact of COVID-19 on HIV Treatment and Research: A Call to Action , 2020, International journal of environmental research and public health.

[81]  Jun Yu Li,et al.  Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[82]  Zhiquan Hu,et al.  Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[83]  R. López-Vélez,et al.  Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort , 2020, The Lancet HIV.

[84]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[85]  P. Calder Nutrition, immunity and COVID-19 , 2020, BMJ Nutrition, Prevention & Health.

[86]  F. Valent,et al.  Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy , 2020, Joint Bone Spine.

[87]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[88]  Meilin Liu,et al.  Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis , 2020, Journal of Infection.

[89]  M. Kamboj,et al.  COVID-19 in Children With Cancer in New York City. , 2020, JAMA oncology.

[90]  A. Vincent-Salomon,et al.  COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area , 2020, Breast Cancer Research.

[91]  L. Trupin,et al.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.

[92]  L. Barreiro,et al.  Herd Immunity: Understanding COVID-19 , 2020, Immunity.

[93]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[94]  A. Paradiso,et al.  MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance , 2020, International journal of molecular sciences.

[95]  A. Vacca,et al.  Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside , 2020, International journal of molecular sciences.

[96]  V. Lougaris,et al.  A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia , 2020, Journal of Allergy and Clinical Immunology.

[97]  H. Miyashita,et al.  Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City , 2020, Annals of Oncology.

[98]  M. Chiarini,et al.  Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[99]  C. Wang,et al.  Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China , 2020, Annals of Oncology.

[100]  S. Gangemi,et al.  IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases , 2019, International journal of molecular sciences.

[101]  G. Mufti,et al.  Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag , 2019, Haematologica.

[102]  F. Dammacco,et al.  Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. , 2017, Clinical immunology.

[103]  F. Goodrum,et al.  Known unknowns: how might the persistent herpesvirome shape immunity and aging? , 2017, Current opinion in immunology.

[104]  C. Weyand,et al.  Aging of the Immune System. Mechanisms and Therapeutic Targets. , 2016, Annals of the American Thoracic Society.

[105]  S. I. Alam,et al.  Secretome, surfome and immunome: emerging approaches for the discovery of new vaccine candidates against bacterial infections , 2016, World journal of microbiology & biotechnology.

[106]  Brandon J Thomas,et al.  Age-Related Gene Expression Differences in Monocytes from Human Neonates, Young Adults, and Older Adults , 2015, PloS one.

[107]  Ruslan Medzhitov,et al.  Homeostasis, Inflammation, and Disease Susceptibility , 2015, Cell.

[108]  L. Notarangelo Primary immunodeficiencies (PIDs) presenting with cytopenias. , 2009, Hematology. American Society of Hematology. Education Program.